Compass Pathways President Steps Down To An Advisory Role
Compass Pathways (Nasdaq: CMPS) announced this morning major changes to its executive team. One of its co-founders, President and Chief Business
Read moreCompass Pathways (Nasdaq: CMPS) announced this morning major changes to its executive team. One of its co-founders, President and Chief Business
Read moreCompass Pathways (NASDAQ: CMPS) this morning issued a brief release, indicating it has been granted a fifth patent in the
Read moreEarlier this month, Compass Pathways (Nasdaq: CMPS) announced positive topline results and its key findings in its Phase 2b clinical
Read moreCompass Pathways (Nasdaq: CMPS) announced today that its phase IIb clinical trial of COMP360 psilocybin therapy has achieved its primary endpoint.
Read moreCompass Pathways (Nasdaq: CMPS) this morning announced that it will be launching the phase II clinical trial for its synthetic psilocybin
Read moreCompass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the latest status of its ongoing
Read moreEight Capital recently produced a primer on the psychedelic sector saying that the companies are “poised to fill a growing
Read moreToday on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt, a highly experienced neuropsychopharmacologist, the
Read moreToday on the Daily Dive, Jeff Stevens returns to the show to sit down with host Cassandra Leah to discuss
Read moreIn terms of investment dollar inflows, one of the largest focuses of 2020 has arguably been that of the growing
Read more